Hims & Hers stock has risen by 20% after announcing a partnership to sell the popular weight-loss drug Wegovy.

Telehealth company Hims & Hers reported first-quarter results late Monday that beat Wall Street estimates. But parts of the ...

Stocks fell on Tuesday as Wall Street reacted to the latest round of tariff uncertainty and some mixed earnings reports.These ...

Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 20.2% in the afternoon session after the company reported ...

But Hims & Hers' shares fell in after-hours trading as second-quarter projections fell short of analysts' expectations. The ...

Hims & Hers Health, Inc.'s Q1 results show 111% growth, yet shares fell 8%. Click for a look at the impact of drug access, ...

Hims & Hers Health, Inc.'s subscriber growth, Novo Nordisk partnership, and FDA pill approval could boost financials. Click ...

Hims & Hers shares fell in extended trading on Monday after the company reported first-quarter earnings that offered soft ...

Hims & Hers launched a pharmacy-made weight-loss drug last year, taking advantage of an FDA rule allowing it to temporarily ...

Hims & Hers Health (NYSE:HIMS) reported a strong financial performance for Q1 2025, with revenue reaching $586 million, ...

Novo Nordisk said it would sell its popular weight-loss drug Wegovy on several telehealth platforms, including Hims.